Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Masters of Immunology

  • Masters of Immunology
    Modification of Cell Differentiation, One of the Mechanisms in the Surveillance of Malignancy
    Eva Klein, Noemi Nagy and Eahsan Rasul
    Cancer Immunol Res February 1 2015 3 (2) 97-102; DOI:10.1158/2326-6066.CIR-14-0238

Cancer Immunology at the Crossroads: Microbiology

  • Cancer Immunology at the Crossroads: Microbiology
    Microbiota Modulation of Myeloid Cells in Cancer Therapy
    Romina S. Goldszmid, Amiran Dzutsev, Sophie Viaud, Laurence Zitvogel, Nicholas P. Restifo and Giorgio Trinchieri
    Cancer Immunol Res February 1 2015 3 (2) 103-109; DOI:10.1158/2326-6066.CIR-14-0225

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures | Free Article
    PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation
    Nemanja Rodić, Robert A. Anders, James R. Eshleman, Ming-Tseh Lin, Haiying Xu, Jung H. Kim, Katie Beierl, Shuming Chen, Brandon S. Luber, Hao Wang, Suzanne L Topalian, Drew M. Pardoll and Janis M. Taube
    Cancer Immunol Res February 1 2015 3 (2) 110-115; DOI:10.1158/2326-6066.CIR-14-0145

    Rodić and colleagues analyzed archival melanocytic lesions and cultured melanomas and found no correlation between melanocyte PD-L1 expression and BRAF V600E mutation, indicating that distinct biomarkers should be used to select patients for BRAF inhibitor and PD-1/PD-L1 checkpoint blockade therapies.

Priority Brief

  • Priority Brief
    Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
    Melissa M. Berrien-Elliott, Jinyun Yuan, Lauryn E. Swier, Stephanie R. Jackson, Collin L. Chen, Maureen J. Donlin and Ryan M. Teague
    Cancer Immunol Res February 1 2015 3 (2) 116-124; DOI:10.1158/2326-6066.CIR-14-0159

    Berrien-Elliott and colleagues report that combination checkpoint blockade induced expression of T-bet and Eomes but only T-bet was required to restore CD8+ antitumor effector function, leading to a >95% cure rate in leukemia-bearing mice given this immunotherapy regimen.

Research Articles

  • Research Articles
    The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
    Michael Hudecek, Daniel Sommermeyer, Paula L. Kosasih, Anne Silva-Benedict, Lingfeng Liu, Christoph Rader, Michael C. Jensen and Stanley R. Riddell
    Cancer Immunol Res February 1 2015 3 (2) 125-135; DOI:10.1158/2326-6066.CIR-14-0127

    Hudecek, Sommermeyer, and colleagues show that modifications of the length and composition of the extracellular spacer of a chimeric antigen receptor (CAR) that abrogate its binding to Fc receptors can prevent off-target activation of CAR T cells and enhance their antitumor efficacy.

  • Research Articles | AuthorChoice
    Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
    Li Shen, Anette Sundstedt, Michael Ciesielski, Kiersten Marie Miles, Mona Celander, Remi Adelaiye, Ashley Orillion, Eric Ciamporcero, Swathi Ramakrishnan, Leigh Ellis, Robert Fenstermaker, Scott I. Abrams, Helena Eriksson, Tomas Leanderson, Anders Olsson and Roberto Pili
    Cancer Immunol Res February 1 2015 3 (2) 136-148; DOI:10.1158/2326-6066.CIR-14-0036

    Shen, Sundstedt, and colleagues show in murine models that tasquinimod enhanced the antitumor effects of SurVaxM tumor vaccine for prostate cancer and of 5T4Fab-SEA tumor-targeted superantigen for melanoma by inhibiting the accumulation and function of tumor-infiltrating suppressive myeloid cells.

  • Research Articles | AuthorChoice
    Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
    Shihao Chen, Li-Fen Lee, Timothy S. Fisher, Bart Jessen, Mark Elliott, Winston Evering, Kathryn Logronio, Guang Huan Tu, Konstantinos Tsaparikos, Xiaoai Li, Hui Wang, Chi Ying, Mengli Xiong, Todd VanArsdale and John C. Lin
    Cancer Immunol Res February 1 2015 3 (2) 149-160; DOI:10.1158/2326-6066.CIR-14-0118

    Chen, Lee, and colleagues compared the antitumor activity of anti-PD-1 in combination with anti-4-1BB versus with anti-LAG-3 and showed in syngeneic, poorly immunogenic mouse tumor models that the combination with anti-4-1BB elicited superior and well-tolerated tumor inhibition that did not require vaccine.

  • Research Articles
    Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC
    Scot D. Liu, Cecile Chalouni, Judy C. Young, Teemu T. Junttila, Mark X. Sliwkowski and John B. Lowe
    Cancer Immunol Res February 1 2015 3 (2) 173-183; DOI:10.1158/2326-6066.CIR-14-0125

    Liu and colleagues show that afucosylated antibodies potentiate ADCC by increasing the cytotoxic rate and number of NK cells capable of killing multiple targets, which results from increased affinity between antibodies and FcγRIIIa to enhance activation of signaling molecules that promote cytoskeletal rearrangement and degranulation.

  • Research Articles | AuthorChoice
    B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity
    Ramtin Rahbar, Albert Lin, Magar Ghazarian, Helen-Loo Yau, Sangeetha Paramathas, Philipp A. Lang, Anita Schildknecht, Alisha R. Elford, Carlos Garcia-Batres, Bernard Martin, Hal K. Berman, Wey L. Leong, David R. McCready, Michael Reedijk, Susan J. Done, Naomi Miller, Bruce Youngson, Woong-Kyung Suh, Tak W. Mak and Pamela S. Ohashi
    Cancer Immunol Res February 1 2015 3 (2) 184-195; DOI:10.1158/2326-6066.CIR-14-0113

    Rahbar and colleagues show that B7-H4 promotes antitumor immunity against mouse mammary cancer and insulinomas and that its expression levels correlate with those of MHC class I in mouse and human tumors; high B7-H4 expression is associated with improved recurrence-free survival in breast cancer patients.

  • Research Articles
    Cell-free Tumor Microparticle Vaccines Stimulate Dendritic Cells via cGAS/STING Signaling
    Huafeng Zhang, Ke Tang, Yi Zhang, Ruihua Ma, Jingwei Ma, Yong Li, Shunqun Luo, Xiaoyu Liang, Tiantian Ji, Zhichao Gu, Jinzhi Lu, Wei He, Xuetao Cao, Yonghong Wan and Bo Huang
    Cancer Immunol Res February 1 2015 3 (2) 196-205; DOI:10.1158/2326-6066.CIR-14-0177

    Zhang, Tang, Zhang, and colleagues report that wide-spectrum antitumor immunity from vaccination with tumor microparticles (T-MP) or T-MP–loaded dendritic cells (DC) is mediated by the cGAS/STING DNA-sensing innate immune pathway and production of type I IFN, which promotes DC maturation and tumor-antigen presentation.

  • Research Articles
    Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
    Carolina Berger, Daniel Sommermeyer, Michael Hudecek, Michael Berger, Ashwini Balakrishnan, Paulina J. Paszkiewicz, Paula L. Kosasih, Christoph Rader and Stanley R. Riddell
    Cancer Immunol Res February 1 2015 3 (2) 206-216; DOI:10.1158/2326-6066.CIR-14-0163

    Berger and colleagues adoptively transferred autologous ROR1 chimeric antigen receptor-modified T (CAR-T) cells into nonhuman primates to demonstrate the safety, persistence, and function of ROR1 CAR-T cells in vivo, and the utility of the model for preclinical testing of novel CARs.

Research Article

  • Research Article
    Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
    Ivan Théate, Nicolas van Baren, Luc Pilotte, Pierre Moulin, Pierre Larrieu, Jean-Christophe Renauld, Caroline Hervé, Ilse Gutierrez-Roelens, Etienne Marbaix, Christine Sempoux and Benoît J. Van den Eynde
    Cancer Immunol Res February 1 2015 3 (2) 161-172; DOI:10.1158/2326-6066.CIR-14-0137

Correction

  • Correction
    Correction: Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
    Cancer Immunol Res February 1 2015 3 (2) 217-217; DOI:10.1158/2326-6066.CIR-15-0007

Back to top
PreviousNext
Cancer Immunology Research: 3 (2)
February 2015
Volume 3, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Masters of Immunology
  • Cancer Immunology at the Crossroads: Microbiology
  • Cancer Immunology Miniatures
  • Priority Brief
  • Research Articles
  • Research Article
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Characterization of Murine Syngeneic Tumor Models
  • PD-L1 in Triple-Negative Breast Cancer
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement